Physician profile
Robert M Holbrook
NPI 1053352054
$11,908.93
in general payments reported to CMS, 2019-2025
33 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $1,219 · 2021: $2,128 · 2022: $2,265 · 2023: $1,759 · 2024: $1,951 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,381.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,474.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,574.62 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,438.23 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,030.49 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $683.64 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $411.71 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $377.15 | 2019-2022 | |
| Qol Medical, LLC | $339.38 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $268.25 | 2019-2022 | |
| Genzyme Corporation | $225.68 | 2022-2025 | |
| Steris Corporation | $219.78 | 2021 | |
| Pfizer INC. | $201.23 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $195.00 | 2021-2023 | |
| Medtronic, INC. | $188.80 | 2024-2025 | Interstim |
| Regeneron Healthcare Solutions, INC. | $168.40 | 2023-2025 | Dupixent |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $153.56 | 2020-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $134.57 | 2021-2023 | Dificid |
| Aimmune Therapeutics, INC. | $128.27 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $98.63 | 2019-2023 | Suflave |
| Madrigal Pharmaceuticals | $94.43 | 2024-2025 | Resmetirom, Rezdiffra |
| Ardelyx, INC. | $93.08 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $87.03 | 2019-2021 | |
| Lilly USA, LLC | $85.68 | 2025 | Omvoh |
| Olympus America INC. | $77.13 | 2019-2024 | Endoclot Phs |
| Phathom Pharmaceuticals, INC. | $30.95 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $28.10 | 2021-2022 | |
| Ucb, INC. | $26.91 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.38 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $16.35 | 2025 | Iqirvo |
| Amag Pharmaceuticals, INC. | $15.92 | 2021 | |
| Organon LLC | $12.08 | 2022 | |
| Cook Medical LLC | $11.87 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Holbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.